HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stada Grows In Russia And CIS With Takeda Brands

Executive Summary

Stada will pay $660m for a basket of 20 brands from Takeda to expand its consumer health portfolio in Russia and a number of strategically important CIS markets.

You may also be interested in...



Stada’s Acquisition Spree Continues With Deal For Ukrainian Probiotics Player

Germany's Stada will gain a range of probiotics and other OTC brands through the acquisition of Ukraine's Biopharma. The deal is Stada's third in the space of just one month. 

Stada Plots Eastern European Expansion With Walmark Deal

Stada is set to snap up Czech Republic-based Walmark in its second major deal this year as it looks to make good on its promise to rapidly expand its OTC-focused Branded Products business. 

Takeda Offloads Emerging Market OTCs to Acino

Takeda is shedding some unwanted OTC assets in a number of emerging markets as part of its efforts to pay down debt and focus its portfolio following its acquisition of Shire. 

Topics

Related Companies

UsernamePublicRestriction

Register

RS149399

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel